Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Shu-Feng Zhou, Jun-Ping Liu & Balram Chowbay. (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews 41:2, pages 89-295.
Read now
Read now
M. Miura, K. Otani & T. Ohkubo. (2005) Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam. Xenobiotica 35:5, pages 455-465.
Read now
Read now
Fu-Chuo Peng, Chaing Hsin-Hui, Tang Sheng-Hui, Chen Pei-Chun & Lu Shao-Chun. (2004) Nadph-Cytochrome P-450 Reductase is Involved in Flunitrazepam Reductive Metabolism in Hep G2 and Hep 3b Cells. Journal of Toxicology and Environmental Health, Part A 67:2, pages 109-124.
Read now
Read now
M. Miura & T. Ohkubo. (2004) In vitro metabolism of quazepam in human liver and intestine and assessment of drug interactions. Xenobiotica 34:11-12, pages 1001-1011.
Read now
Read now
Slobodan Rendic. (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabolism Reviews 34:1-2, pages 83-448.
Read now
Read now
Articles from other publishers (20)
Maurice Wilde, Volker Auwärter & Bjoern Moosmann. (2021) New psychoactive substances—Designer benzodiazepines. WIREs Forensic Science 3:6.
Crossref
Crossref
Rahul Patel, James Barker & Amr ElShaer. (2020) Pharmaceutical Excipients and Drug Metabolism: A Mini-Review. International Journal of Molecular Sciences 21:21, pages 8224.
Crossref
Crossref
Bjoern Moosmann & Volker Auwärter. 2018. New Psychoactive Substances. New Psychoactive Substances
383
410
.
Jui-Kang Tsai, Chia-Nan Yen, Cheng-Sheng Chen, Tzung-Jeng Hwang, Shao-Tsu Chen, Tzu-Ting Chen, Chih-Hung Ko, Po-Wen Su, Yu-Ping Chang, Jin-Jia Lin & Cheng-Fang Yen. (2017) Prevalence and clinical correlates of flunitrazepam-related complex sleep behaviors. Psychiatry and Clinical Neurosciences 71:3, pages 198-203.
Crossref
Crossref
Maria Katselou, Ioannis Papoutsis, Panagiota Nikolaou, Chara Spiliopoulou & Sotiris Athanaselis. (2016) Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam. Forensic Toxicology 35:1, pages 1-10.
Crossref
Crossref
Béla Kiss, Catalina Bogdan, Anca Pop & Felicia Loghin. (2012) A rapid UPLC–MS/MS method for simultaneous determination of flunitrazepam, 7-aminoflunitrazepam, methadone and EDDP in human, rat and rabbit plasma. Talanta 99, pages 649-659.
Crossref
Crossref
David E. Moody. 2012. Handbook of Drug Interactions. Handbook of Drug Interactions
25
116
.
Dan Li, Yonglong Han, Xiangle Meng, Xipeng Sun, Qi Yu, Yan Li, Lili Wan, Yan Huo & Cheng Guo. (2010) Effect of Regular Organic Solvents on Cytochrome P450-Mediated Metabolic Activities in Rat Liver Microsomes: Fig. 1.. Drug Metabolism and Disposition 38:11, pages 1922-1925.
Crossref
Crossref
Arun K. Tiwari, Renan P. Souza & Daniel J. Müller. (2009) Pharmacogenetics of anxiolytic drugs. Journal of Neural Transmission 116:6, pages 667-677.
Crossref
Crossref
T. Fukasawa, A. Suzuki & K. Otani. (2007) Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. Journal of Clinical Pharmacy and Therapeutics 32:4, pages 333-341.
Crossref
Crossref
M Iwase, N Kurata, R Ehana, Y Nishimura, T Masamoto & H Yasuhara. (2016)
Evaluation of the effects of hydrophilic organic solvents on CYP3A-mediated drug-drug interaction
in vitro
. Human & Experimental Toxicology 25:12, pages 715-721.
Crossref
Crossref
Sharon J. Gardiner & Evan J. Begg. (2006) Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice. Pharmacological Reviews 58:3, pages 521-590.
Crossref
Crossref
Ophelia Q. P. Yin, Brian Tomlinson, Albert H. L. Chow, Mary M. Y. Waye & Moses S. S. Chow. (2013) Omeprazole as a CYP2C19 Marker in Chinese Subjects: Assessment of Its Gene‐Dose Effect and Intrasubject Variability. The Journal of Clinical Pharmacology 44:6, pages 582-589.
Crossref
Crossref
Mark R. Hutchinson, Andrew Menelaou, David J. R. Foster, Janet K. Coller & Andrew A. Somogyi. (2003) CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. British Journal of Clinical Pharmacology 57:3, pages 287-297.
Crossref
Crossref
Toshimasa TanakaNaomi KamiguchiTeruaki OkudaYoshio Yamamoto. (2004) Characterization of the CYP2C8 Active Site by Homology Modeling. Chemical and Pharmaceutical Bulletin 52:7, pages 836-841.
Crossref
Crossref
David E. Moody. 2004. Handbook of Drug Interactions. Handbook of Drug Interactions
3
88
.
I. Gafni, U. E. Busto, R. F. Tyndale, H. L. Kaplan & E. M. Sellers. (2003) The Role of Cytochrome P450 2C19 Activity in Flunitrazepam Metabolism In Vivo. Journal of Clinical Psychopharmacology 23:2, pages 169-175.
Crossref
Crossref
Zeruesenay Desta, Xiaojiong Zhao, Jae-Gook Shin & David A. Flockhart. (2002) Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism. Clinical Pharmacokinetics 41:12, pages 913-958.
Crossref
Crossref
Karthik Venkatakrishnan, Lisa L. von Moltke & David J. Greenblatt. (2013) Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models. The Journal of Clinical Pharmacology 41:11, pages 1149-1179.
Crossref
Crossref
Chin‐Eng Ong, Sally Coulter, Donald J. Birkett, C. Ramana Bhasker & John O. Miners. (2008) The xenobiotic inhibitor profile of cytochrome P4502C8. British Journal of Clinical Pharmacology 50:6, pages 573-580.
Crossref
Crossref